Phaseline

Targets › CSNK1E

CSNK1E (Casein kinase I isoform epsilon): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 3 Phase 2, 1 Phase 1; Oncology; next expected readout Jan 2027.

Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates (Probable). Participates in Wnt signaling. (UniProt, P49674)

Open in Phaseline: the race on CSNK1E, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Umbralisib
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 2Grade 1 Follicular LymphomaJan 2027
City of Hope Medical CenterUmbralisib
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 2Mantle Cell LymphomaJul 2027
Jennifer R. Brown, MD, PhDUmbralisib
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 2Chronic Lymphocytic LeukemiaJan 2028
University of ChicagoUmbralisib (TGR-1202)
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 1CLLDec 2027

Conditions

Mantle Cell Lymphoma (1) Chronic Lymphocytic Leukemia (1) Grade 1 Follicular Lymphoma (1) CLL (1)

Modalities

mixed (4)

Companies

City of Hope Medical Center (1) Jennifer R. Brown, MD, PhD (1) National Cancer Institute (NCI) (1) University of Chicago (1)

Related targets

PIK3CD (4) ABL1 (4)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.